Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4343174#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B786270.
- aggregation creator B786271.
- aggregation creator B786272.
- aggregation creator B786273.
- aggregation creator B786274.
- aggregation creator person.
- aggregation date "2014".
- aggregation format "application/pdf".
- aggregation hasFormat 4343174.bibtex.
- aggregation hasFormat 4343174.csv.
- aggregation hasFormat 4343174.dc.
- aggregation hasFormat 4343174.didl.
- aggregation hasFormat 4343174.doc.
- aggregation hasFormat 4343174.json.
- aggregation hasFormat 4343174.mets.
- aggregation hasFormat 4343174.mods.
- aggregation hasFormat 4343174.rdf.
- aggregation hasFormat 4343174.ris.
- aggregation hasFormat 4343174.txt.
- aggregation hasFormat 4343174.xls.
- aggregation hasFormat 4343174.yaml.
- aggregation isPartOf urn:issn:0961-5423.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)".
- aggregation abstract "Erlotinib has been shown to prolong progression-free (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). We report here on effectiveness data on the subsample of 261 patients from 40 centres in Belgium involved in the TRUST study. Median age was 63 years. Most (69.0%) were male and current/former smokers (84.7%); with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (74.3%), stage IV disease (75.1%) and adenocarcinoma by histology (54.0%). Erlotinib was administered mainly as second- (47.1%) or third-line treatment (48.3%). Response rate was 6.5%; disease control rate 58.3%. Median PFS was 2.2 months. Better PS (P = 0.0384), stage IIIB disease (P = 0.0018) and presence of rash (P < 0.0001) were associated with longer PFS. OS rates at 1, 2 and 3 years were 26.4%, 10.9% and 6.4% respectively. Median OS was 5.9 months. Female gender (P = 0.007), better PS (P < 0.0001), stage IIIB disease (P = 0.0355) and presence of rash (P < 0.0001) were associated with longer OS. The findings confirm the therapeutic benefit of erlotinib in a broad range of patients in a sample from a country with a historically high lung cancer morbidity and mortality burden. Several determinants of PFS and OS are identified.".
- aggregation authorList BK1157286.
- aggregation endPage "379".
- aggregation issue "3".
- aggregation startPage "370".
- aggregation volume "23".
- aggregation aggregates 4343207.
- aggregation isDescribedBy 4343174.
- aggregation similarTo ecc.12146.
- aggregation similarTo LU-4343174.